ANNEXON INC. - COMMON

Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference

19 Sep 2023 05:30:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

18 Sep 2023 15:01:00 By Nasdaq GlobeNewswire

Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results

07 Aug 2023 05:30:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

02 Aug 2023 15:01:00 By Nasdaq GlobeNewswire

Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy

30 Jul 2023 11:00:00 By Nasdaq GlobeNewswire

Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer

27 Jul 2023 05:30:00 By Nasdaq GlobeNewswire

Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function

24 May 2023 15:01:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 May 2023 15:01:00 By Nasdaq GlobeNewswire

Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress

08 May 2023 15:01:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference

11 Apr 2023 05:30:00 By Nasdaq GlobeNewswire

Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

06 Mar 2023 05:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference

27 Feb 2023 05:30:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

17 Jan 2023 15:30:00 By Nasdaq GlobeNewswire

Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises

08 Jan 2023 08:00:00 By Nasdaq GlobeNewswire

Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio

06 Jan 2023 05:30:00 By Nasdaq GlobeNewswire

Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 05:30:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

17 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023

03 Nov 2022 05:30:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

18 Oct 2022 15:01:00 By Nasdaq GlobeNewswire